

# Nanobiotix

Corporate update

## Data, dollars and development updates

Pharma & biotech

During 2014 Nanobiotix continued to progress lead product NBTXR3, with positive data leading to a refined development strategy that could allow for first CE mark approval in STS in Europe by 2016. Capital increases and additional future commitments should allow Nanobiotix to continue with its recently expanded NBTXR3 development strategy and go-it-alone US commercial plans. During 2015 we expect more NBTXR3 clinical data from ongoing trials and the start of further trials under the current strategy.

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/12	1.0	(5.2)	(0.65)	0.0	N/A	N/A
12/13	1.6	(8.1)	(0.75)	0.0	N/A	N/A
12/14e	1.9	(8.9)	(0.71)	0.0	N/A	N/A
12/15e	3.1	(12.2)	(0.86)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

### STS development plans refined during 2014

Following positive NBTXR3 data in the pilot soft tissue sarcoma (STS) trial, Nanobiotix recently started a pivotal study in c 180 patients as part of the strategy to bring NBTXR3 to market in Europe by the end of 2016 (via a CE mark process). Existing Asia-Pacific partner PharmaEngine has also elected to participate in the trial. Interim data could become available in H116 and could trigger the start of a potential bridging study in the US, depending on the data.

### Expanded strategy broadens NBTXR3's potential

Aside from the ongoing clinical trials (STS pivotal study and head and neck pilot study), towards the end of 2014 Nanobiotix announced expanded development plans to include liver cancers (hepatocellular carcinoma HCC, and liver metastases) and high-risk prostate cancer, broadening NBTXR3's potential. Nanobiotix also intends to pursue NBTXR3 commercialisation alone in the US.

### NBTXR3 data and strategy execution in 2015

During H115 interim data from the ongoing head and neck pilot study could become available, which could then be followed by a pivotal study. In addition, US/EU pilot studies in both liver cancers and high-risk prostate cancer could potentially start in H215. Further development of NBTXR3 will be funded by cash raised during 2014, which most recently includes €10.4m from a strategic US investor, with future potential commitments of €24.1m (€14.1m through warrants), which will also support the strategy to commercialise NBTXR3 alone the US.

### Valuation: No changes to €464m rNPV

We make no changes to our €464m (€33/share) risk-adjusted NPV-based valuation, which includes NBTXR3 commercialised by Nanobiotix in both the US and Europe in the various planned indications included within the current strategy (STS, head and neck, liver cancers and high-risk prostate cancers).

9 January 2015

**Price** €17.49  
**Market cap** €247m

Net cash (€m) at end June 2014	25.7
Shares in issue	14.1m
Free float	41%
Code	NANO
Primary exchange	Euronext Paris
Secondary exchange	N/A

#### Share price performance



%	1m	3m	12m
Abs	1.3	(8.7)	257.5
Rel (local)	3.7	(11.7)	253.9
52-week high/low	€24.44	€4.83	

#### Business description

Nanobiotix is a French nanotechnology company developing radiotherapy enhancers for the treatment of cancer. Lead product NBTXR3 has completed pilot clinical STS development in Europe and is partnered with PharmaEngine in Asia-Pacific.

#### Next events

Interim head and neck data	H115
Start of pilot trials in prostate and liver cancers	H215
Expansion of STS trial to additional countries	2015
Interim STS data	H116

#### Analysts

Dr Philippa Gardner	+44 (0)20 3681 2521
Dr Mick Cooper	+44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

## Valuation

We have made no changes to our recently updated Nanobiotix valuation of €464m, or €33/share. This includes NBTXR3 in the various indications being pursued under the current development plan (STS, head and neck cancer, liver cancers and high-risk prostate cancer), which we assume will be commercialised alone in the US and Europe. Our combined US/EU peak NBTXR3 sales are €1.4bn. Our valuation also includes a contribution for the partnership with PharmaEngine in Asia-Pacific in indications that we believe could be pursued in this region. The breakdown of our rNPV valuation, which uses a 12.5% discount rate, is shown in Exhibit 1.

Exhibit 1: Nanobiotix rNPV valuation							
Product	Indication	Launch	Peak sales (€m)	NPV (€m)	Probability	rNPV (€m)	rNPV/share (€/share)
NBTXR3 – US/Europe	STS	2016	190	184.3	60%	108.4	7.7
	Head & neck	2019	350	301.3	40%	113.7	8.1
	Liver cancers including liver mets	2021	500	266.0	40%	99.9	7.1
	Prostate cancer	2021	400	213.4	40%	80.7	5.7
NBTXR3 – Asia	STS; rectal; oesophageal; liver cancer	2017	300	63.8	40%	25.5	1.8
Pro forma net cash				35.6	100%	35.6	2.5
<b>Valuation</b>				<b>1,064.3</b>		<b>463.7</b>	<b>33.0</b>

Source: Edison Investment Research

### Commercialisation alone in the US and Europe

Nanobiotix always intended to commercialise NBTXR3 alone in Europe and at the end of 2014 following the private placement in the US, announced plans to also commercialise alone in the US (partnering could still be an option in the future, but would be dependent on the terms of any deal). Hence our forecasts and valuation were adjusted in our [last note](#) to reflect this updated strategy, reflecting the full development costs and a sales and marketing infrastructure, rather than a simple royalty. Although at the time of launch this will require a higher initial cash outlay to build a salesforce, this strategy will likely be far more profitable than a partnership in the longer term.

Our valuation is split in the US and Europe by each indication that is being developed or is in the development plan. These include STS, where we assign a 60% probability of success, commensurate with a Phase III asset. NBTXR3 is regulated as a medical device in Europe, rather than as a drug and hence the pivotal study in Europe should be the final stage of development before approval. For all other indications (head and neck cancer, liver cancers and high-risk prostate cancer), we assign a 40% probability of success. The development status of each indication is as follows:

- **Soft tissue sarcoma (STS):** a pivotal STS study in 180 patients recently began following approval in France, with expansion across Europe (funded by Nanobiotix) to additional countries as further approvals are granted. Partner PharmaEngine is funding recruitment in Asia-Pacific. Interim data from this trial are expected in H116 followed by full data and CE mark approval as a medical device in Europe potentially by end 2016. This could lead to initial self-pay sales in STS, with full reimbursement likely sought once survival data become available in other indications, potentially 12-18 months later. A bridging study could start in the US once interim data become available.
- **Head and neck cancer:** a pilot trial in head and neck cancer is ongoing and interim data could become available during H115. This could provide NBTXR3 proof-of-concept in another indication. If positive, a pivotal study could potentially start from 2016.

- **Liver cancers (HCC and liver metastases):** a pilot study in this indication could start in H215, which if positive could lead to pivotal development in 2017 and potential launch in 2021. Liver metastases (tumours arising in the liver from the spread of other primary cancers such as colorectal cancer, breast cancer, lung cancer etc) could be a significant opportunity for NBTXR3, as for example in colorectal cancer alone there are nearly 150k new cases in the US each year, with around 50% who develop hepatic metastases. We more conservatively assume around 100k liver metastases patients in the US and Europe who could be eligible for NBTXR3.
- **High-risk prostate cancer:** similar to liver cancers, a pilot study in this indication could also start in H215, with potential launch in 2021.

Our forecasts in Asia continue to assume partner PharmaEngine will develop NBTXR3 in a number of indications, which include STS and could include rectal, oesophageal and liver cancer (the precise indications to be developed have not yet been disclosed).

## Financials

---

We have made no changes to our last published financial forecasts, which include R&D spend for each of indications included in our valuation. These include: (1) the recently started pivotal STS trial in Europe; a bridging study could start in the US in H216, which is incorporated in our forecasts; (2) the pilot head and neck trial that is ongoing in Europe and could be followed by a pivotal US/European trial in 2016, which is factored in our forecasts; and (3) €2-3m spend for pilot trials in each of liver and prostate cancers, which we assume will start in H215.

We also include the build-out of a commercial infrastructure in Europe in 2016 in readiness for launch at end 2016/early 2017, although this is likely to be quite limited in the early part of launch.

Our unchanged forecasts continue to suggest current net cash of around €35.6m (based on reported net cash at end June of €25.7m together with the estimated net proceeds of €9.9m from the recent private placement) should be sufficient to fund operations to H216, assuming development continues in all planned indications. This could potentially be met by the €10m commitment from Capital Ventures International (CVI) as part of the recent private placement, the terms of which are summarised below (we do not include this future commitment or the exercise of the warrants in our financial forecasts):

- **€10.4m private placement:** Nanobiotix secured €10.4m cash through a private placement to CVI in December through the issuance of 650k shares at €15.99/share (we assume net proceeds of c €9.9m).
- **650k warrants could raise €14.1m:** a warrant is attached to each new share, with an exercise price of €21.63, which could raise a further €14.1m. These warrants expire on 30 June 2016 and can be exercised by CVI at any point before expiry. Nanobiotix can require CVI to exercise the warrants if Nanobiotix's share price is >€32.45 for 20 days in a 30-trading day period.
- **A further €10m could be raised in the future:** CVI has committed to purchase up to a further €10m of new shares (up to 650k shares) between 25 November 2015 and 31 March 2016. By this point additional data from STS and from head and neck could be available, both of which will help to inform decisions on the future clinical development.

**Exhibit 2: Financial summary**

	€000s	2009	2010	2011	2012	2013	2014e	2015e	2016e
Year end December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>									
Revenue		2,768	1,135	1,360	971	1,595	1,928	3,103	7,130
Cost of Sales		(95)	0	0	0	0	0	0	(143)
Gross Profit		2,673	1,135	1,360	971	1,595	1,928	3,103	6,987
Research and development		(3,443)	(4,186)	(5,213)	(4,312)	(6,026)	(7,500)	(12,000)	(26,000)
Selling, general and administration		(729)	(1,045)	(1,375)	(1,811)	(3,749)	(3,600)	(3,708)	(11,375)
EBITDA		(1,295)	(3,935)	(5,030)	(5,006)	(7,945)	(9,020)	(12,432)	(30,192)
Operating Profit (before amort. and except.)		(1,490)	(4,092)	(5,213)	(5,146)	(8,171)	(9,163)	(12,594)	(30,376)
Intangible Amortisation		(9)	(4)	(14)	(7)	(8)	(9)	(11)	(12)
Exceptionals		0	0	0	0	0	0	0	0
Other		(1)	(0)	(0)	(22)	0	0	0	0
Operating Profit		(1,499)	(4,096)	(5,227)	(5,175)	(8,179)	(9,172)	(12,605)	(30,389)
Net Interest		(10)	11	(19)	(77)	34	285	434	58
Profit Before Tax (norm)		(1,500)	(4,081)	(5,233)	(5,223)	(8,137)	(8,877)	(12,160)	(30,318)
Profit Before Tax (FRS 3)		(1,510)	(4,086)	(5,247)	(5,252)	(8,145)	(8,887)	(12,170)	(30,331)
Tax		0	0	0	(79)	18	0	0	0
Profit After Tax (norm)		(1,501)	(4,081)	(5,233)	(5,324)	(8,118)	(8,877)	(12,160)	(30,318)
Profit After Tax (FRS 3)		(1,510)	(4,086)	(5,247)	(5,331)	(8,126)	(8,887)	(12,170)	(30,331)
Average Number of Shares Outstanding (m)		4.5	6.8	7.7	8.2	10.8	12.4	14.1	14.1
EPS - normalised (€)		(0.3)	(0.6)	(0.68)	(0.65)	(0.75)	(0.71)	(0.86)	(2.15)
EPS - normalised and fully diluted (€)		(0.3)	(0.6)	(0.68)	(0.65)	(0.75)	(0.71)	(0.86)	(2.15)
EPS - (IFRS) (€)		(0.3)	(0.6)	(0.68)	(0.65)	(0.76)	(0.72)	(0.86)	(2.15)
Dividend per share (€)		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		96.6	100.0	100.0	100.0	100.0	100.0	100.0	98.0
EBITDA Margin (%)		-46.8	-346.7	-369.7	-515.8	-498.0	-467.9	-400.6	-423.4
Operating Margin (before GW and except.) (%)		-53.8	-360.6	-383.3	-530.2	-512.2	-475.3	-405.8	-426.0
<b>BALANCE SHEET</b>									
Fixed Assets		569	682	580	485	545	641	625	766
Intangible Assets		6	2	7	0	9	17	23	28
Tangible Assets		540	638	511	416	468	556	534	670
Investments		23	42	63	69	68	68	68	68
Current Assets		3,096	7,253	2,333	13,539	6,894	36,240	26,780	4,895
Stocks		0	0	0	0	0	0	0	0
Debtors		0	0	0	1	1	1	2	4
Cash		1,084	649	899	12,361	5,002	34,348	24,887	3,000
Other		2,012	6,604	1,434	1,177	1,891	1,891	1,891	1,891
Current Liabilities		(1,214)	(1,539)	(1,415)	(2,160)	(3,282)	(4,093)	(4,933)	(2,933)
Creditors		(1,027)	(1,349)	(1,119)	(1,800)	(3,051)	(3,843)	(4,683)	(2,683)
Short term borrowings		(187)	(190)	(295)	(360)	(231)	(250)	(250)	(250)
Long Term Liabilities		(522)	(505)	(573)	(1,167)	(975)	(1,725)	(3,280)	(13,566)
Long term borrowings		(500)	(474)	(527)	(1,072)	(875)	(1,625)	(3,175)	(13,466)
Other long term liabilities		(22)	(31)	(46)	(95)	(100)	(100)	(104)	(100)
Net Assets		1,928	5,891	926	10,697	3,182	31,063	19,193	(10,838)
<b>CASH FLOW</b>									
Operating Cash Flow		(1,667)	(4,157)	(4,862)	(3,786)	(6,837)	(7,932)	(11,288)	(31,898)
Net Interest		(89)	13	(7)	(119)	(18)	285	434	58
Tax		0	0	0	0	0	5	0	0
Capex		(97)	(245)	(60)	(45)	(196)	(231)	(140)	(321)
Acquisitions/disposals		0	0	0	1	4	(17)	(17)	(17)
Financing		2,722	8,011	15	14,807	14	36,468	0	0
Dividends		0	0	0	0	0	0	0	0
Net Cash Flow		869	3,621	(4,914)	10,858	(7,034)	28,577	(11,011)	(32,178)
Opening net debt/(cash)		(540)	(396)	15	(76)	(10,929)	(3,895)	(32,473)	(21,462)
HP finance leases initiated		0	0	0	0	0	0	0	0
Other		(1,013)	(4,033)	5,006	(5)	0	0	0	0
Closing net debt/(cash)		(396)	15	(76)	(10,929)	(3,895)	(32,473)	(21,462)	10,716

Source: Nanobiotix accounts, Edison Investment Research. Note: Long-term liabilities include our future fund-raising estimate of €10m in 2016, assuming all clinical trials progress as planned. This could potentially be met by commitments from the strategic US investor, Capital Ventures International (CVI).

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Nanobiotix and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.